Buy Like Buffett
Watchlist

Core Scientific, Inc./tx

CORZ · Other · $4.2B mkt cap · FY2025 filings · · No moat ·

Doesn't clear the bar

No moat
Share / Embed this score
Embed this score

The five investor questions

20

2021–2025 (latest 5 aligned FYs; v3 window cap 5): revenue $544M to $319M, decreasing; diluted EPS 0.20 to -0.88, decreasing.

7

Median gross margin 19.6% over 6y, variable.

0

Median ROIC 0.9%, above the 12% hurdle in 0% of years.

55

Net cash position — no leverage risk.

24

Owner earnings changed trend unclear over up to the ten most recent annual observations.

Price vs. value if growth stopped today

A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.

Above value if growth stopped todayBelow value if growth stopped today
No price data
Not reported
Unavailable — insufficient owner-earnings data
Unavailable — insufficient growth-model data
$13.48
No price data

This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. The recent FY revenue series does not trigger the three-consecutive-declines flag.

Among the current top-score group, the median current price is 243% above the zero-growth estimate across 49 of the current top 50 companies by Moat Score with both values.

Score records captured Oct 18, 2026.

Exactly which 50 companies?

FTNT, IBEX, META, MEDP, MSFT, GOOG, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, CPRT, VEEV, RMD, GRMN, PCTY, EAT, UI, SSD, MNST, DOCS, LRCX, MCO, NTAP, NVDA, CORT, SFM, MPTI, ULTA, SN, ROL, CTAS, PAYC, IRMD, DECK, MORN, INTU, JKHY, TPR, LGCY, DAL, GWW, ISRG, MPWR, LOPE

Missing a usable price or zero-growth estimate: ANF.

Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.

7 years of fundamentals

The business, in plain English

Core Scientific, Inc./tx booked $319M of revenue in FY2025 in the Other sector and kept 11.9% of it as gross profit — a thin-margin business by that measure. After every other cost, −90.5% of each revenue dollar reached the bottom line.

Across the filed record, revenue grew from $60.3M (FY2020) to $319M (FY2025) — about 39.5% a year compounded over 5 years.

CORZ's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.

Put together: Balance-Sheet Safety is the strongest of the five filters (55/100) and Returns on Capital the weakest (0/100), which is how CORZ lands at 21/100 — a None moat.

This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.

FY2019–FY2025 · 7 fiscal years, normalized from CORZ’s SEC filings

Sales, as filed$319M FY2025
$0$250M$500M2019202120232025
Revenue kept after cost of goods11.9% FY2025
0%20%40%2019202120232025
Standard ROIC or separately labeled Operating ROIC

Exact FY and FY-1 financing invested-capital inputs are required.

Exact FY and FY-1 financing invested-capital inputs are required.

Cash an owner could take out−$289M FY2025
−$2B−$1B$02019202120232025

The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.

Flagship explainer

How Core Scientific, Inc./tx makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$319M · 100%Cost of revenue$281M · 88%Gross profit$37.9M · 12%Operating income−$246M · −77%Income before tax−$288M · −90%Income tax$583000 · 0%Net income−$289M · −90%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$319M100%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Cost of revenue$281M88%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
$37.9M12%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
−$246M−77%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Income before tax−$288M−90%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Income tax$5830000%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
−$289M−90%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

Flagship explainer

What Core Scientific, Inc./tx owns — and owes

Core Scientific, Inc./tx's filing tags don't support a full breakdown — here's what is filed:

Table alternative
Filed lineValue% of assetsSource
Total assets$2.3B100%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Cash and equivalents$311M13%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Stockholders’ equity−$963M−41%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set

Flagship explainer

What drives Core Scientific, Inc./tx’s return on equity?

ROE is five filed business factors multiplied together.

DuPont return on equity factor treeReturn on equity branches into tax burden, interest burden, operating margin, asset turnover, and the equity multiplier.Return on equity27%Tax burden100%net income ÷ pretax incomeInterest burden117%pretax ÷ operating incomeOperating margin−77%operating income ÷ revenueAsset turnover0.21×revenue ÷ average assetsEquity multiplier-1.40×average assets ÷ average equityAs of 2025-12-31 · 2 SEC filing sourcesBuy Like Buffett · buylikebuffett.com
DuPont source inputs
InputValueFiscal yearSource
−$289MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Income before tax−$288MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Operating income−$246MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
$319MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Ending assets$2.3BFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Beginning assets$664MFY2024
−$963MFY2025
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
−$1.2BFY2024
Source: · event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set
Embed this chart

Flagship explainer

Where Core Scientific, Inc./tx's cash went

Core Scientific, Inc./tx’s filing does not supply enough provenance-matched cash-flow lines for a truthful flow chart — here’s what is filed:

Table alternative
Filed lineValue% of cash from operationsSource
Cash from operations$278M100%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Depreciation and amortization$68.9M25%
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001628280-26-013305 · filed Mar 2, 2026
· event Dec 31, 2025 · retrieved Oct 18, 2026 · annual-row source set

Curated 19-manager tier

Who reported holding Core Scientific, Inc./tx

Delayed public 13F reports for 2026-Q2—not live positions, trades, or recommendations.

0 holding0 exited0 not holding0/19 resolved19 not retrieved

Named manager positions and quarter-over-quarter changes
ManagerReported positionQuarter-over-quarterFiling accession
Abrams CapitalNot retrievedComparison not retrievedFiling not retrieved
Akre CapitalNot retrievedComparison not retrievedFiling not retrieved
Baupost GroupNot retrievedComparison not retrievedFiling not retrieved
Berkshire HathawayNot retrievedComparison not retrievedFiling not retrieved
Brave Warrior AdvisorsNot retrievedComparison not retrievedFiling not retrieved
Dodge & CoxNot retrievedComparison not retrievedFiling not retrieved
First EagleNot retrievedComparison not retrievedFiling not retrieved
FundsmithNot retrievedComparison not retrievedFiling not retrieved
Gardner Russo & QuinnNot retrievedComparison not retrievedFiling not retrieved
Gates Foundation TrustNot retrievedComparison not retrievedFiling not retrieved
Mairs & PowerNot retrievedComparison not retrievedFiling not retrieved
Markel / Markel-GaynerNot retrievedComparison not retrievedFiling not retrieved
Oakmark / Harris AssociatesNot retrievedComparison not retrievedFiling not retrieved
Pershing SquareNot retrievedComparison not retrievedFiling not retrieved
Polen CapitalNot retrievedComparison not retrievedFiling not retrieved
Sequoia / Ruane CunniffNot retrievedComparison not retrievedFiling not retrieved
Southeastern Asset ManagementNot retrievedComparison not retrievedFiling not retrieved
Tweedy, BrowneNot retrievedComparison not retrievedFiling not retrieved
Yacktman Asset ManagementNot retrievedComparison not retrievedFiling not retrieved

Position size uses shares and filed value from each manager’s 13F. Portfolio weight uses the eligible long-share filing denominator. Changes compare only with the immediately preceding calendar quarter.

Source: Filing source not retrieved · event Jun 30, 2026 · retrieved Oct 18, 2026

Flagship explainer

What Core Scientific, Inc./tx insiders reported

We could not retrieve insider activity for this rendering; no zero-activity claim is shown.

Unavailable: Form 4 activity could not be retrieved for this rendering.

Moat Score history

15 logged readings since Sep 4, 2026 · append-only, never rewritten

Moat Score over timeLast scored reading of each day, on the 0–100 scale21.2 / 100
0406080100WideNarrowShallowNo moatSep 4, 2026Oct 18, 2026

Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars

None yet — CORZ has read No moat for every logged capture since Sep 4, 2026.

Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.

Insider activity

Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”

These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.

The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for CORZ.

Other context

#99 of 104 scored Other companies, ranked by Moat Score.

Nearest peers by Moat Score

  1. #97FFR AIxCrypto Holdings, Inc.22.7No moat
  2. #98NBND NETBRANDS CORP.21.9No moat
  3. #100ORBS Eightco Holdings Inc.20.8No moat
  4. #101PAPL PINEAPPLE FINANCIAL INC.19.6No moat

Compare CORZ with its nearest peers →All Other companies on the Index →

Common questions about CORZ

Does Core Scientific, Inc./tx have an economic moat?
Based on its FY2025 SEC filings, the Moat Index scores Core Scientific, Inc./tx (CORZ) 21.2 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 20, pricing power 7, returns on capital 0, balance-sheet safety 55, capital allocation 24.
How has CORZ's Moat Score changed over time?
The record logs 15 readings since Sep 4, 2026; the latest reads 21.2 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell CORZ. See the disclaimer.